Compare Biocon Ltd with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs LUPIN - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LUPIN BIOCON /
LUPIN
 
P/E (TTM) x 25.3 -70.8 - View Chart
P/BV x 2.9 2.1 135.4% View Chart
Dividend Yield % 0.3 0.0 -  

Financials

 BIOCON    LUPIN
EQUITY SHARE DATA
    BIOCON
Mar-19
LUPIN
Mar-19
BIOCON /
LUPIN
5-Yr Chart
Click to enlarge
High Rs707986 71.7%   
Low Rs554720 76.9%   
Sales per share (Unadj.) Rs91.9369.5 24.9%  
Earnings per share (Unadj.) Rs16.713.4 124.7%  
Cash flow per share (Unadj.) Rs24.237.4 64.7%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs101.6303.7 33.5%  
Shares outstanding (eoy) m600.00452.49 132.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x6.92.3 297.1%   
Avg P/E ratio x37.763.6 59.3%  
P/CF ratio (eoy) x26.122.8 114.3%  
Price / Book Value ratio x6.22.8 220.8%  
Dividend payout %6.00-   
Avg Mkt Cap Rs m378,330386,064 98.0%   
No. of employees `0006.117.7 34.7%   
Total wages/salary Rs m11,65331,513 37.0%   
Avg. sales/employee Rs Th8,994.39,453.8 95.1%   
Avg. wages/employee Rs Th1,900.71,782.0 106.7%   
Avg. net profit/employee Rs Th1,635.3343.0 476.8%   
INCOME DATA
Net Sales Rs m55,144167,182 33.0%  
Other income Rs m1,4443,640 39.7%   
Total revenues Rs m56,588170,822 33.1%   
Gross profit Rs m15,88328,822 55.1%  
Depreciation Rs m4,47810,850 41.3%   
Interest Rs m7093,078 23.0%   
Profit before tax Rs m12,14018,534 65.5%   
Minority Interest Rs m9-89 -10.1%   
Prior Period Items Rs m038 0.0%   
Extraordinary Inc (Exp) Rs m0-3,400 0.0%   
Tax Rs m2,1239,017 23.5%   
Profit after tax Rs m10,0266,066 165.3%  
Gross profit margin %28.817.2 167.1%  
Effective tax rate %17.548.7 35.9%   
Net profit margin %18.23.6 501.1%  
BALANCE SHEET DATA
Current assets Rs m48,228138,536 34.8%   
Current liabilities Rs m30,37661,299 49.6%   
Net working cap to sales %32.446.2 70.1%  
Current ratio x1.62.3 70.3%  
Inventory Days Days6884 81.5%  
Debtors Days Days86112 76.0%  
Net fixed assets Rs m64,130127,516 50.3%   
Share capital Rs m3,000905 331.5%   
"Free" reserves Rs m57,980136,517 42.5%   
Net worth Rs m60,980137,422 44.4%   
Long term debt Rs m15,76666,417 23.7%   
Total assets Rs m121,924279,494 43.6%  
Interest coverage x18.17.0 258.1%   
Debt to equity ratio x0.30.5 53.5%  
Sales to assets ratio x0.50.6 75.6%   
Return on assets %8.83.3 269.1%  
Return on equity %16.44.4 372.5%  
Return on capital %16.88.9 188.1%  
Exports to sales %28.10-   
Imports to sales %18.90-   
Exports (fob) Rs m15,506NA-   
Imports (cif) Rs m10,399NA-   
Fx inflow Rs m15,50659,414 26.1%   
Fx outflow Rs m10,39922,282 46.7%   
Net fx Rs m5,10737,132 13.8%   
CASH FLOW
From Operations Rs m11,54616,660 69.3%  
From Investments Rs m-7,138-32,825 21.7%  
From Financial Activity Rs m-2,4177,441 -32.5%  
Net Cashflow Rs m2,103-8,724 -24.1%  

Share Holding

Indian Promoters % 40.4 46.6 86.7%  
Foreign collaborators % 20.6 0.2 10,300.0%  
Indian inst/Mut Fund % 8.4 11.3 74.3%  
FIIs % 10.7 31.9 33.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 10.1 197.0%  
Shareholders   109,995 98,259 111.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   STRIDES PHARMA SCIENCE  ELDER PHARMA  ALEMBIC LTD  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare BIOCON With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Crashes Over 1,400 Points; Nifty Sees Worst Weekly Loss Since 2009(Closing)

It was mayhem on Dalal Street today. India share markets tumbled for the sixth straight session as global sell-off weighed on the benchmark indices.

Related Views on News

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

LUPIN Announces Quarterly Results (2QFY20); Net Profit Down 146.4% (Quarterly Result Update)

Nov 7, 2019 | Updated on Nov 7, 2019

For the quarter ended September 2019, LUPIN has posted a net profit of Rs 1 bn (down 146.4% YoY). Sales on the other hand came in at Rs 44 bn (up 10.3% YoY). Read on for a complete analysis of LUPIN's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

Multibaggers of the Next Decade(The 5 Minute Wrapup)

Feb 26, 2020

The one key ingredient to be seen amongst top multibaggers of the next decade.

The Next Few Days Are Crucial for Smallcap Investors - And 3 Must-Buy Stocks(Profit Hunter)

Feb 19, 2020

While I have been writing about the rebound in smallcaps for quite some time now... I have shied from the question - When exactly is the smallcap rebound happening. Well, the answer is now.

The Top 8 Trading Mistakes You Should Avoid(Fast Profits Daily)

Feb 18, 2020

Avoid these mistakes and your trading will turn much more profitable.

Corona Virus Could Trigger a Rally in this Stock(Profit Hunter)

Feb 20, 2020

A company which benefits from crude oil and coronavirus - if you would like to know more about it read this.

Why I Expect the Coronavirus to Benefit My Latest Trade Recommendation(Fast Profits Daily)

Feb 19, 2020

This is how my latest trade recommendation will benefit from the Coronavirus scare.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Feb 28, 2020 03:37 PM

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS